Company intelligence / Profile preview

Verica Biotech

Ottawa, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Virica Biotech has developed a library of small molecule Viral Sensitizers (VSEs) that significantly increase viral vector yields in cell and gene therapy and vaccine manufacturing. Their internal therapeutics pipeline is preclinical and primarily collaborative for manufacturing enhancements[2][3][4][5].

Therapeutic areas: OtherInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

ReiTheraNational Research Council of CanadaCulture Biosciences

Beyond the preview

Go deeper on Verica Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verica Biotech.

Explore the full profile